How Is The Bredesen Protocol Different Than Traditional Alzheimer’s Treatments?

Therapy for Alzheimer’s Disease should target underlying problems of the disease and not just the protein beta-amyloid plaque.

Traditionally, pharmaceutical companies have been trying to eliminate symptoms of Alzheimer’s Disease by targeting a protein called beta-amyloid plaque.

Drug companies will see reversal of cognitive problems in animal models by reducing amyloid plaque, but this does not translate into the same benefits as it does humans.

The problem with this method is that beta-amyloid plaque is not the root cause of Alzheimer’s, but rather one possible symptom of the disease.

Humans are more complex than animals and beta-amyloid plaque in humans acts as a multi-functional protein (some examples):

• Anti-microbial
• Anti-inflammatory
• Toxin binder (such as heavy metals)

So as I mentioned above, the buildup of beta-amyloid plaque in the brain is one symptom and not the cause of Alzheimer’s Disease.

Instead of targeting beta-amyloid plaque specifically, the strategy to reverse cognitive decline should be a conglomeration of the latest insights of longevity research, which is a major focus in the Bredesen Protocol and Rezilir Health™ Remission of Alzheimer’s Disease (ROAD) Protocol.

Overall, we want to create a more optimal internal environment for general health and longevity by looking at:

• Diet
• Physical activity
• Gene-specific treatment of metabolic dysfunction
• Nutrient deficiencies
• Hormone dysregulation
• Oxidative stress
• Previous and current infections
• Environment